NCT01506596

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Vector Oncology · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effectiveness and safety of single agent pazopanib in subjects with unresectable or metastatic liposarcoma.

Detailed description

This is a Phase II, multicenter, prospective, open label, single arm study. The primary endpoint of the study is progression-free rate as defined by Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.1 at week 12 after start of treatment. The secondary endpoints include overall progression-free survival (PFS), response rate (RR), duration of response, overall survival (OS), and toxicity assessment through the reporting of adverse events.

Conditions

• Liposarcoma
• Surgically Unresectable Liposarcoma
• Metastatic Liposarcoma

Interventions

Type	Name	Description
DRUG	pazopanib	Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.

Timeline

• Start date: 2012-03-01
• Primary completion: 2014-10-01
• Completion: 2016-03-01
• First posted: 2012-01-10
• Last updated: 2017-02-15
• Results posted: 2016-05-25

Locations

9 sites across 1 country: United States